Incyte Corporation (INCY) and Vertex Pharmaceuticals (VRTX) are two prominent U.S. biopharmaceutical companies that offer contrasting risk-and-reward profiles. INCY is a diversified oncology and dermatology player still scaling its newer franchises, while VRTX is a dominant force in cystic fibrosis (CF, a genetic lung disease) that is now investing heavily to expand beyond its core market. This stock comparison is most relevant to healthcare-sector investors and traders weighing growth momentum against franchise stability. Recent market activity, including earnings results, analyst revisions, and pipeline catalysts, has shifted sentiment for both names, making a head-to-head look at their relative performance and market positioning timely.
Incyte Corporation is a biopharmaceutical company focused on oncology, hematology, and dermatology. Its flagship product, Jakafi (ruxolitinib), remains the revenue anchor, while the topical treatment Opzelura has become a fast-growing franchise in atopic dermatitis and vitiligo. In its most recent quarterly report, INCY posted total revenue of roughly $1.51 billion, up 28% year over year, with full-year revenue reaching about $5.14 billion, a 21% increase. Earnings per share (EPS, or profit allocated to each outstanding share) also improved versus the prior-year period.
Sentiment has turned more constructive in recent weeks, with multiple analysts raising price targets and, in some cases, upgrading the stock. The company's pipeline has matured, with regulatory submissions advancing for extended-release and additional indications, and management has guided to continued double-digit growth in key franchises. However, competitive pressure, higher investment in hematology and oncology, and uncertainty around future regulatory approvals remain factors investors are monitoring.
Vertex Pharmaceuticals is a global biotechnology leader best known for its cystic fibrosis (CF) franchise, anchored by Trikafta/Kaftrio and the newer Alyftrek. The company is diversifying through Journavx, a non-opioid acute pain medicine, Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia, and a late-stage kidney-disease pipeline led by povetacicept. In its most recent quarter, VRTX reported total revenue of about $3.08 billion, up 11% year over year, with adjusted EPS ahead of consensus.
Despite solid top-line growth, VRTX shares have faced pressure in recent market activity. Newer products such as Journavx and Casgevy have launched more slowly than some analysts expected, and rising research and development (R&D) plus selling and marketing expenses have compressed operating margins. The CF business remains durable and highly profitable, but investor focus has shifted to whether the company's diversification efforts can reaccelerate growth.
Tickeron maintains hundreds of AI trading bots that collectively monitor and trade thousands of different tickers across varied strategies, timeframes, and risk profiles. Not every bot suits every market environment, which is why only the best-performing and most relevant strategies are featured in the curated Trending AI Robots section. These bots differ meaningfully in trading style, holding period, performance statistics, and the sets of tickers they trade, allowing users to evaluate approaches that align with their own objectives. Traders comparing names like INCY and VRTX may find it useful to observe how automated systems are currently positioned across the healthcare sector.
The two companies diverge sharply in business model and growth profile. INCY is earlier in its diversification cycle, with Jakafi funding growth across a broader oncology and dermatology portfolio, and is posting faster percentage revenue gains. VRTX enjoys a near-monopoly position in CF that generates strong cash flow, but its newer launches have yet to reach the scale investors anticipated, creating a gap between its stable core and its higher-risk growth initiatives.
On momentum, INCY has benefited from a sequence of analyst upgrades and raised targets, while VRTX has contended with margin compression and slower-than-expected new-product uptake. Risk profiles also differ: INCY carries concentration risk in Jakafi and pipeline-execution risk, whereas VRTX faces execution risk tied to diversification beyond CF. Sector exposure overlaps in biotechnology, but the two names respond to different catalysts, making their relative performance a useful lens for healthcare investors.
Based on observable factors including trend consistency, revenue acceleration, analyst sentiment shifts, and near-term catalysts, Tickeron's AI framework currently leans toward INCY over VRTX. INCY's faster growth and improving sentiment momentum appear more favorable to a trend-oriented model, while VRTX's stable but slower core and margin pressures introduce near-term uncertainty. This is a probabilistic assessment of current market positioning rather than a definitive outcome, and relative momentum could shift as new earnings, clinical data, or regulatory events emerge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INCY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 18, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 35 instances where the indicator turned negative. In 22 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 63%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INCY as a result. In 55 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
INCY moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for INCY crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +3.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 205 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 158 of 245 cases where INCY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.823) is normal, around the industry mean (3.596). P/E Ratio (14.717) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (443.347).
Be on the lookout for a price bounce soon.
The 10-day moving average for VRTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +1.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 235 of 368 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
VRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 180 of 286 cases where VRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The 10-day RSI Indicator for VRTX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 23 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRTX as a result. In 46 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 52%.
The Moving Average Convergence Divergence Histogram (MACD) for VRTX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In 31 of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
VRTX moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.848) is normal, around the industry mean (3.596). P/E Ratio (31.605) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (443.347).
INCY | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 28 | 13 | |
SMR RATING 1..100 | 33 | 41 | |
PRICE GROWTH RATING 1..100 | 45 | 42 | |
P/E GROWTH RATING 1..100 | 69 | 42 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VRTX's Valuation (91) in the Biotechnology industry is in the same range as INCY (92). This means that VRTX’s stock grew similarly to INCY’s over the last 12 months.
VRTX's Profit vs Risk Rating (13) in the Biotechnology industry is in the same range as INCY (28). This means that VRTX’s stock grew similarly to INCY’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is in the same range as VRTX (41). This means that INCY’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's Price Growth Rating (42) in the Biotechnology industry is in the same range as INCY (45). This means that VRTX’s stock grew similarly to INCY’s over the last 12 months.
VRTX's P/E Growth Rating (42) in the Biotechnology industry is in the same range as INCY (69). This means that VRTX’s stock grew similarly to INCY’s over the last 12 months.
| INCY | VRTX | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 53% |
| Stochastic ODDS (%) | 1 day ago 62% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 57% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 63% | 1 day ago 52% |
| TrendWeek ODDS (%) | 1 day ago 59% | 1 day ago 42% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 67% |
| Advances ODDS (%) | 11 days ago 63% | 11 days ago 64% |
| Declines ODDS (%) | 1 day ago 56% | 3 days ago 43% |
| BollingerBands ODDS (%) | 1 day ago 57% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 64% | 1 day ago 63% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 2 FA rating(s) are green while VRTX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 5 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).
INCY (@Biotechnology) experienced а -4.79% price change this week, while VRTX (@Biotechnology) price change was -4.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -9.27%. For the same industry, the average monthly price growth was -14.83%, and the average quarterly price growth was -25.31%.
INCY is expected to report earnings on Feb 09, 2027.
VRTX is expected to report earnings on Feb 09, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.